| Literature DB >> 27009263 |
Wafa Kammoun-Rebai1,2, Ikbel Naouar2,3, Valentina Libri4, Matthew Albert4,5,6, Hechmi Louzir2,3,7, Amel Meddeb-Garnaoui1, Darragh Duffy8,9,10.
Abstract
BACKGROUND: A successful host immune response to infection is dependent upon both innate and adaptive immune effector mechanisms. Cutaneous leishmaniasis results in an adaptive Th1 CD4(+) T cell response that efficiently clears the parasite, but may also result in scaring. However the role of innate mechanisms during parasite clearance remains less well defined.Entities:
Keywords: Asymptomatic infection; Leishmaniasis; Protein biomarkers
Mesh:
Substances:
Year: 2016 PMID: 27009263 PMCID: PMC4806467 DOI: 10.1186/s12879-016-1458-6
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Demographic and clinical features of the study population
| Cutaneous Leishmania (LST + SCAR+) | Asymptomatic (LST + SCAR-) | Naïve (LST-SCAR-) | |
|---|---|---|---|
| - Donor numbers | 17 | 23 | 18 |
| - Age, mean ± SD (range), years | 12.9 ± 3.5 (7–18) | 13.2 ± 3.6 (7–18) | 13.3 ± 4.4 (7–18) |
| - Zoonotic Cutaneous Leishmaniasis scars | yes | no | no |
| - Leishmanin Skin Test (LST) positive | yes | yes | no |
| - LST induration, mean ± SD (range), mm | 12.3 ± 4.5 (5,5-21) | 12.1 ± 5.6 (5–24,5) | 0,1 ± 0,7 (0–3) |
Fig. 1Characterization of the adaptive immune response in LST+ individuals. Secreted cytokines, (a) IFN-γ, (b) IL-2, (c) IL-18, (d) IL-12p70, and (e) IL-13 measured by Luminex assays following Leishmania parasite stimulation of PBMCs from donors subdivided into 3 clinical groups, according to the Leishmanin skin test response (LST+/−) and presence or absence of specific scars (SCAR+/−). (***) denotes p < 0.001 as determined by Wilcoxon paired T test, samples with no measurable value were given a value that was half of the lowest detectable dose of the assays)
The sensitivity, specificity, positive predictive values, and negative predictive values of the induced cytokine response for IFNγ, IL-2, IL-18, IL-12p70, and IL-13 for identifying LST+ (n = 40) individuals as compared to LST- (n = 16) with a 95 % confidence interval
| Sensitivity | Specificity | Positive predictive value | Negative predictive value | |
|---|---|---|---|---|
| IFN-γ | 0.86 | 0.92 | 0.97 | 0.66 |
| IL-2 | 0.76 | 0.85 | 0.97 | 0.33 |
| IL-18 | 0.87 | 0.76 | 0.9 | 0.72 |
| IL-12p70 | 0.92 | 0.48 | 0.57 | 0.88 |
| IL-13 | 0.86 | 1.00 | 1.00 | 0.66 |
Fig. 2Shared induced innate immune responses across all 3 clinical groups. Secreted cytokines significantly induced (Wilcoxon paired T test, p < 0.05) (a) MIP-1α, (b) IL-1β, (c) M-CSF, (d) IL-10, (e) IL-17A, (f) TNFα, (g) IL-5, and (h) GMCSF measured by Luminex assays following Leishmania parasite stimulation of PBMCs from donors subdivided into 3 clinical groups, according to the Leishmanin skin test response (LST+/−) and presence or absence of specific scars (SCAR+/−). (*** denotes p < 0.001, ** p < 0.01, * p < 0.05 as determined by Kruskal Wallis test with Dunn’s multiple testing between the 3 groups, samples with no measurable value were given a value that was half of the lowest detectable dose of the assays)
Fig. 3Lack of induced response to Leishmania parasite for key inflammatory molecules. Cytokines (a) IL-6, (b) IL-8 with no differences as measured by Luminex assays following parasite stimulation of PBMCs from donors subdivided into 3 clinical groups, according to the Leishmanin skin test response (LST+/−) and presence or absence of specific scars (SCAR+/−)
Fig. 4Multivariate protein analysis. Principal component analysis (PCA) of LST + SCAR+ (blue), LST + SCAR- (yellow), and LST-SCAR- (pink) donors (a) based on the 10 most significantly differential proteins as identified by multi ANOVA (q < 0.01), (b) heat map overlay of IFN-γ expression. PCA of (c) LST + SCAR+ (blue) and LST-SCAR- (pink) donors, (d) LST + SCAR- (yellow) and LST-SCAR- (pink) donors. Numbers represent percentage of variance captured by each principal component. (e) List of most differential proteins with p and q values as determined by multi ANOVA testing